David Jacoby

David Jacoby is an experienced pharmaceutical executive who recently joined Ultragenyx as the Senior Vice President (SVP) and Head of Clinical Development.2 Here's a comprehensive overview of his professional background:

Education and Early Career

David Jacoby holds an M.D. and Ph.D. in Molecular Biology from the University of Pennsylvania School of Medicine, as well as a B.A. in Biology from Swarthmore College.1 His early career included:

• Research Fellow in Viral Immunopathology at The Scripps Research Institute
• Resident in Adult Neurology at Massachusetts General Hospital
• Clinical Fellow in the Movement Disorders Unit at Massachusetts General Hospital
• Research Fellow in Molecular Neurogenetics at Massachusetts General Hospital

Professional Experience

Dr. Jacoby has an extensive career in the pharmaceutical industry, with a focus on clinical development and rare diseases:

BioMarin Pharmaceutical Inc.: He held several leadership positions at BioMarin from 2012 to 2023, including:

• Group Vice President, BioMarin Fellow
• Fellow; Vice President Discovery Medicine
• VP, Clinical Sciences Fellow, Head of Clinical Sciences
• Executive Group Director, Clinical Sciences
• Senior Medical Group Leader Neuroscience

During his tenure at BioMarin, he led the clinical development group, oversaw development stage pipeline projects, and coordinated portfolio assessments.1 He was also involved in discovery, diligence, and business development activities aimed at increasing pipeline and research programs.

Repligen Corporation: Prior to BioMarin, Dr. Jacoby worked at Repligen Corporation from 2006 to 2012, where he served as:

• Head of Clinical Development
• Medical Director

At Repligen, he was responsible for clinical development programs in various areas, including pancreatic imaging, bipolar depression, spinal muscular atrophy, and Friedreich's ataxia.1

Other Roles:

• Medical Director at Serono, Inc. (2000-2001)
• Associate Neurologist at Massachusetts General Hospital (1998-2000)
• Independent Consultant (2001-2006)

Current Position

As of August 1, 2024, David Jacoby started a new position as Head of Clinical Development at Ultragenyx.2 This role likely involves overseeing the clinical development strategies and programs for Ultragenyx's pipeline of treatments for rare and ultra-rare diseases.

Expertise and Contributions

Dr. Jacoby has extensive experience in:

• Clinical development for rare and neurogenetic diseases
• Translational research in neuroscience and rare disorders
• Regulatory submissions and presentations
• Business development, including in- and out-licensing
• Leadership of research and early development teams

His work has contributed to successful drug registrations, including Brineura for the CLN2 form of Batten's disease.1 He has also been involved in multiple programs for conditions such as PKU, MPS III, hemophilia A, and Friedreich's ataxia.